Immunogenicity of OmpA and OmpB antigens from Rickettsia rickettsii on mononuclear cells from Rickettsia positive Mexican patients

Dzul-Rosado, Karla; Balam-Romero, Javier; Valencia-Pacheco, Guillermo; Lugo–Caballero, César; Arias-León, Juan; Peniche-Lara, Gaspar; Zavala-Castro, Jorge

doi:10.4103/0972-9062.225836

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on vaccine and diagnostic test development studies, 14–16 the OmpB protein of Rickettsia rickettsii (WP_012151219.1) was used and compared to determine its similarity and intraspecies conservation with seven human pathogenic species: Rickettsia felis, Rickettsia akari, Rickettsia typhi, Rickettsia prowazekii, Rickettsia slovaca, Rickettsia conorii, and Rickettsia parkeri , which were selected based on their identification in reported human cases of rickettsioses in Mexico and the Americas. A second BLASTp analysis was performed with other organisms ( Leptospira sp , Dengue virus, Zika virus, and Chikungunya virus) to identify and exclude similar protein regions of other pathogens.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of multi-peptide sequences identifiedin silicofor the serological identification of antibodies against Vector-Borne Diseases

Peña-Bates,

Lugo-Caballero,

Pavía-Ruz

et al. 2024

Preprint

View full text Add to dashboard Cite

The socio-ecological conditions of Mexican regions are conducive to the spread of vector-borne diseases. Although there are established treatment guidelines for dengue and rickettsiosis, diagnosis is complicated. The objective of this work was to identify epitopes of Rickettsia and Dengue virus that could be used in serology screening against vector-borne diseases. For this, epitopes with high HLA-II binding efficiency of OmpB protein of Rickettsia rickettsii and NS2B protein of dengue virus were identified in silico through a reverse vaccinology strategy. The selected epitopes were grouped into multi-peptide sequences that were synthesized and immobilized in a nitrocellulose membrane to evaluate the reactivity sera from patients previously infected with dengue or Rickettsia. The evaluation of the sequences of the NS2B and OmpB proteins was performed with 60 sera previously diagnosed as positive or negative by the respective gold standard techniques. The dot blot technique was used for the antigenic evaluation of the peptides against these serum samples. Dot blot analysis correctly identified 85% of sera positive for rickettsiosis and 75% of sera positive for dengue. Reverse vaccinology reduces the time and cost of antigen discovery. Experimental evidence from multi-peptide sequences suggests their potential use in the development of diagnostic tests for dengue and rickettsiosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of multi-peptide sequences identifiedin silicofor the serological identification of antibodies against Vector-Borne Diseases

Peña-Bates,

Lugo-Caballero,

Pavía-Ruz

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Of particular interest is outer membrane protein B (OmpB/Sca5), which is recognized by convalescent serum from laboratory animals and patients previously infected with R. typhi ( Dasch and Bourgeois, 1981 ). Additionally, T cells from R. typhi infected patients secrete IL-2 and IFNγ in response to macrophages expressing fragments of R. rickettsii OmpB, suggesting recognition of peptides presented by MHCI by CD8+ T cells and cross-reactivity of T cells to conserved OmpB epitopes between TG and SFG rickettsiae ( Dzul-Rosado et al., 2017 ). Guinea pigs vaccinated with OmpB from R. typhi are protected from homologous challenge ( Dasch et al., 1984 ).…”

Section: Typhus Group Vaccinesmentioning

confidence: 99%

Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria

van Schaik,

Fratzke,

Gregory

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Obligate intracellular bacteria have remained those for which effective vaccines are unavailable, mostly because protection does not solely rely on an antibody response. Effective antibody-based vaccines, however, have been developed against extracellular bacteria pathogens or toxins. Additionally, obligate intracellular bacteria have evolved many mechanisms to subvert the immune response, making vaccine development complex. Much of what we know about protective immunity for these pathogens has been determined using infection-resolved cases and animal models that mimic disease. These studies have laid the groundwork for antigen discovery, which, combined with recent advances in vaccinology, should allow for the development of safe and efficacious vaccines. Successful vaccines against obligate intracellular bacteria should elicit potent T cell memory responses, in addition to humoral responses. Furthermore, they ought to be designed to specifically induce strong cytotoxic CD8+ T cell responses for protective immunity. This review will describe what we know about the potentially protective immune responses to this group of bacteria. Additionally, we will argue that the novel delivery platforms used during the Sars-CoV-2 pandemic should be excellent candidates to produce protective immunity once antigens are discovered. We will then look more specifically into the vaccine development for Rickettsiaceae, Coxiella burnetti, and Anaplasmataceae from infancy until today. We have not included Chlamydia trachomatis in this review because of the many vaccine related reviews that have been written in recent years.

show abstract

“…OmpA and OmpB are considered immunodominant antigens that are recognized by T and B cells from experimentally infected animals as well as from humans suffering from rickettsioses. For example, different OmpB fragments from R. rickettsii were expressed in THP-1 MF, and T cells from patients that were positively tested for the presence of R. rickettsii, R. typhi, or R. felis by PCR/restriction fragment length polymorphism (RFLP) reacted to these cells with enhanced IL-2 and IFNγ production and induced IL-12p70, IL-6, and TNFα in the antigen-expressing THP-1 MF [193]. This response is likely to be ascribed mainly to CD8 + T cells because expression of the OmpB fragments in the cells results in MHCI presentation.…”

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

The neglected challenge: Vaccination against rickettsiae

Osterloh

2020

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Over the last decades, rickettsioses are emerging worldwide. These diseases are caused by intracellular bacteria. Although rickettsioses can be treated with antibiotics, a vaccine against rickettsiae is highly desired for several reasons. Rickettsioses are highly prevalent, especially in poor countries, and there are indications of the development of antibiotic resistance. In addition, some rickettsiae can persist and cause recurrent disease. The development of a vaccine requires the understanding of the immune mechanisms that are involved in protection as well as in immunopathology. Knowledge about these immune responses is accumulating, and efforts have been undertaken to identify antigenic components of rickettsiae that may be useful as a vaccine. This review provides an overview on current knowledge of adaptive immunity against rickettsiae, which is essential for defense, rickettsial antigens that have been identified so far, and on vaccination strategies that have been used in animal models of rickettsial infections.

show abstract

Immunogenicity of OmpA and OmpB antigens from Rickettsia rickettsii on mononuclear cells from Rickettsia positive Mexican patients

Cited by 8 publications

References 0 publications

Evaluation of multi-peptide sequences identifiedin silicofor the serological identification of antibodies against Vector-Borne Diseases

Evaluation of multi-peptide sequences identifiedin silicofor the serological identification of antibodies against Vector-Borne Diseases

Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria

The neglected challenge: Vaccination against rickettsiae

Contact Info

Product

Resources

About